Figure 1 - uploaded by Leandro Bueno Bergantin
Content may be subject to copyright.
![Pharmacological modulation of the Ca 2+ /cAMP signaling interaction proposed by Caricati-Neto and Bergantin [26-30]. The Ca 2+ /cAMP signaling interaction can be pharmacologically modulated by combined use of the the Ca 2+ channel blockers (CCB) and drugs that promote the increase of [cAMP] c (cAMP-enhancer compounds).](profile/Leandro-Bergantin/publication/320086656/figure/fig1/AS:616362410012673@1523963658214/Pharmacological-modulation-of-the-Ca-2-cAMP-signaling-interaction-proposed-by.png)
Pharmacological modulation of the Ca 2+ /cAMP signaling interaction proposed by Caricati-Neto and Bergantin [26-30]. The Ca 2+ /cAMP signaling interaction can be pharmacologically modulated by combined use of the the Ca 2+ channel blockers (CCB) and drugs that promote the increase of [cAMP] c (cAMP-enhancer compounds).
Source publication
Cancer is a major public health problem and the second leading cause of mortality around the world. Antitumor immunotherapy using monoclonal antibodies is considered selective and efficient in the treatment of different types of tumors, but its cost and toxic effects limit its application. Many tumor microenvironments, including lymphoma and carcin...
Context in source publication
Context 1
... we have proposed that the combined use of monoclonal antibodies with drugs that modulate the Ca 2+ /cAMP signaling interaction to reduce tumor growth could be potential strategy in the antitumor immunotherapy due to increment of antitumor efficacy and reduction of adverse effects [31][32][33][34][35][36][37]. Figure 1 shows how the Ca 2+ /cAMP signaling interaction could be pharmacologically modulated by the combined use of the Ca 2+ channel blockers (CCB) and drugs that promote the increase of [cAMP] c (cAMP-enhancer compounds). ...
Citations
... Cancer is the second leading global cause of death that inflicts more people every year as lifestyles change and breast cancer is the most prevalent cancer type among females, with one in every eight women suffering from it in their lifetime. 1,2 The current clinical cancer therapies including chemotherapy, radiotherapy, and surgery lack the desirable effectiveness and are associated with severe side effects. [3][4][5] For these reasons, finding an improved cancer therapy method has been the subject of extensive research efforts worldwide. ...
Introduction: To date, numerous iron-based nanostructures have been designed for cancer therapy applications. Although some of them were promising for clinical applications, few efforts have been made to maximize the therapeutic index of these carriers. Herein, PEGylated silica-coated iron oxide nanoparticles (PS-IONs) were introduced as multipurpose stimuli-responsive co-delivery nanocarriers for a combination of dual-drug chemotherapy and photothermal therapy.
Methods: Superparamagnetic iron oxide nanoparticles were synthesized via the sonochemical method and coated by a thin layer of silica. The nanostructures were then further modified with a layer of di-carboxylate polyethylene glycol (6 kDa) and carboxylate-meth-oxy polyethylene glycol (6 kDa) to improve their stability, biocompatibility, and drug loading capability. Doxorubicin (DOX) and cisplatin (CDDP) were loaded on the PS-IONs through the interactions between the drug molecules and polyethylene glycol.
Results: The PS-IONs demonstrated excellent cellular uptake, cytocompatibility, and hemocompatibility at the practical dosage. Furthermore, in addition to being an appropriate MRIagent, PS-IONs demonstrated superb photothermal property in 0.5 W/cm2of 808 nm laser irradiation. The release of both drugs was effectively triggered by pH and NIR irradiation. Asa result of the intracellular combination chemotherapy and 10 min of safe power laser irradiation, the highest cytotoxicity for iron-based nanocarriers (97.3±0.8%) was achieved.
Conclusion: The results of this study indicate the great potential of PS-IONs as a multi-functional targeted co-delivery system for cancer theranostic application and the advantage of employing proper combination therapy for cancer eradication.
... Cancer is the second leading global cause of death that inflicts more people every year as the lifestyle changes (Caricati-neto et al. 2017;Li et al. 2017a) Current main clinical cancer treatment methods, namely chemotherapy, radiotherapy, and surgery, do not provide satisfactory outcomes and are associated with some limitations as well as inconvenience for the patients as a result of their far-reaching side effects (Zhang et al. 2015d;Wang et al. 2016aWang et al. , 2017aRen et al. 2017). Thus, in order to improve the full treatment chance, chemotherapy is usually supplemented by other methods (Jing et al. 2018). ...
During the last few decades, nanotechnology has established many essential applications in the biomedical field and in particular for cancer therapy. Not only can nanodelivery systems address the shortcomings of conventional chemotherapy such as limited stability, non-specific biodistribution and targeting, poor water solubility, low therapeutic indices, and severe toxic side effects, but some of them can also provide simultaneous combination of therapies and diagnostics. Among the various therapies, the combination of chemo- and photothermal therapy (CT-PTT) has demonstrated synergistic therapeutic efficacies with minimal side effects in several preclinical studies. In this regard, inorganic nanostructures have been of special interest for CT-PTT, owing to their high thermal conversion efficiency, application in bio-imaging, versatility, and ease of synthesis and surface modification. In addition to being used as the first type of CT-PTT agents, they also include the most novel CT-PTT systems as the potentials of new inorganic nanomaterials are being more and more discovered. Considering the variety of inorganic nanostructures introduced for CT-PTT applications, enormous effort is needed to perform translational research on the most promising nanomaterials and to comprehensively evaluate the potentials of newly introduced ones in preclinical studies. This review provides an overview of most novel strategies used to employ inorganic nanostructures for cancer CT-PTT as well as cancer imaging and discusses current challenges and future perspectives in this area.
